Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults with type 1 diabetes, has not been well-evaluated in those with type 2 diabetes receiving insulin. Objective: To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin. Design: Randomized clinical trial. (The protocol also included a type 1 diabetes cohort in a parallel trial and subsequent second trial.) (ClinicalTrials.gov: NCT02282397). Setting: 25 endocrinology practices in North America. Patients: 158 adults who had had type 2 diabetes for a median of 17 years (interquartile range, 11 to 23 years). Participants were aged 35 to 79 years (mean, 60 years [SD, 10]), were receiving multiple daily injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5%). Intervention: Random assignment to CGM (n = 79) or usual care (control group, n = 79). Measurements: The primary outcome was HbA1c reduction at 24 weeks. Results: Mean HbA1c levels decreased to 7.7% in the CGM group and 8.0% in the control group at 24 weeks (adjusted difference in mean change, -0.3% [95% CI, -0.5% to 0.0%]; P = 0.022). The groups did not differ meaningfully in CGM-measured hypoglycemia or quality-of-life outcomes. The CGM group averaged 6.7 days (SD, 0.9) of CGM use per week. Limitation: 6-month follow-up. Conclusion: A high percentage of adults who received multiple daily insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had improved glycemic control. Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support an additional management method that may benefit these patients. Primary Funding Source: Dexcom.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefits of CGM in this population include reductions in A1C, fewer severe hypoglycemia events in children and adults, increased TIR, as well as significant reductions in hospitalizations for severe hypoglycemia and DKA.156,162–168”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“The clinical efficacy of CGM has been demonstrated in numerous retrospective studies and RCTs of individuals with T1D regardless of insulin delivery method.156–161”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“In addition, CGM use has been reported to reduce fear of hypoglycemia and increase confidence in avoiding/treating hypoglycemia.156,174,175”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [4]
In the citing paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [4]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Assessing Psychosocial Distress in Diabetes
Polonsky, W. H., Fisher, L., Earles, J., Dudl, R. J., Lees, J., Mullan, J., & Jackson, R. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.626 · Cited by 1,575
Self-citationContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 3×
“org), was identical to that of a parallel trial in patients with type 1 diabetes (12), which also had a second phase assessing insulin pump initiation.”
BackgroundResultSelf-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Cited by
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Self-citationAmiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543
Self-citationLu, J., Ma, X., Zhou, J., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1131 · Cited by 517
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationThe fallacy of average: how using HbA1c alone to assess glycemic control can be misleading
Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017) · Diabetes Care · doi:10.2337/dc17-0636 · Cited by 477
Self-citationThe relationship of hemoglobin A1C to time-in-range in patients with diabetes
Vigersky, R. A., & McMahon, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0310 · Cited by 464
Maiorino, M. I., Signoriello, S., Maio, A., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2020) · Diabetes Care · doi:10.2337/dc19-1459 · Cited by 364
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
Wearable Devices in Cardiovascular Medicine
Hughes, A., Shandhi, M. M. H., Master, H., Dunn, J., & Brittain, E. (2023) · Circulation Research · doi:10.1161/circresaha.122.322389 · Cited by 291
Klonoff, D. C., Wang, J., Rodbard, D., Kohn, M. A., Li, C., Liepmann, D., Kerr, D., Ahn, D., Peters, A. L., Umpierrez, G. E., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221085273 · Cited by 295
Self-citationLee, I., Probst, D., Klonoff, D., & Sode, K. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113054 · Cited by 288
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
7. Diabetes Technology: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s007 · Cited by 250
Šoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0888 · Cited by 242
Silbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Yaron, M., Roitman, E., Aharon-Hananel, G., Landau, Z., Ganz, T., Yanuv, I., Rozenberg, A., Karp, M., Ish-Shalom, M., Singer, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-0166 · Cited by 211
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
Measures of Accuracy for Continuous Glucose Monitoring and Blood Glucose Monitoring Devices
Freckmann, G., Pleus, S., Grady, M., Setford, S., & Levy, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818812062 · Cited by 202
Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring
Edelman, S. V., Argento, N. B., Pettus, J., & Hirsch, I. B. (2018) · Diabetes Care · doi:10.2337/dc18-1150 · Cited by 199
Wadwa, R. P., Laffel, L. M., Shah, V. N., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0150 · Cited by 198
Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus
Lin, R., Brown, F., James, S., Jones, J., & Ekinci, E. (2021) · Diabetic Medicine · doi:10.1111/dme.14528 · Cited by 197
Karter, A. J., Parker, M. M., Moffet, H. H., Gilliam, L. K., & Dlott, R. (2021) · JAMA · doi:10.1001/jama.2021.6530 · Cited by 191
Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis
Jancev, M., Vissers, T. A. C. M., Visseren, F. L. J., van Bon, A. C., Serné, E. H., DeVries, J. H., de Valk, H. W., & van Sloten, T. T. (2024) · Diabetologia · doi:10.1007/s00125-024-06107-6 · Cited by 191
Digital diabetes: Perspectives for diabetes prevention, management and research
Fagherazzi, G., & Ravaud, P. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.012 · Cited by 188
Evans, M., Welsh, Z., Ells, S., & Seibold, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00720-0 · Cited by 185
Galindo, R. J., Migdal, A. L., Davis, G. M., Urrutia, M. A., Albury, B., Zambrano, C., Vellanki, P., Pasquel, F. J., Fayfman, M., Peng, L., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2073 · Cited by 181
Shah, V. N., Laffel, L. M., Wadwa, R. P., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0143 · Cited by 197
7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Positioning time in range in diabetes management
Advani, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05027-0 · Cited by 170
Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline
Galindo, R. J., Umpierrez, G. E., Rushakoff, R. J., Basu, A., Lohnes, S., Nichols, J. H., Spanakis, E. K., Espinoza, J., Palermo, N. E., Awadjie, D. G., et al. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820954163 · Cited by 170
Alva, S., Bailey, T., Brazg, R., Budiman, E. S., Castorino, K., Christiansen, M. P., Forlenza, G., Kipnes, M., Liljenquist, D. R., & Liu, H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820958754 · Cited by 164
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 199
Christiansen, M. P., Klaff, L. J., Brazg, R., Chang, A. R., Levy, C. J., Lam, D. W.-H., Denham, D. S., Atiee, G. J., Bode, B. W., Walters, S. J., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0142 · Cited by 155
Management of hypoglycemia in older adults with type 2 diabetes
Freeman, J. S. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1578590 · Cited by 169
Continuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology
Galindo, R. J., & Aleppo, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108502 · Cited by 156
Phillip, M., Bergenstal, R. M., Close, K. L., Danne, T., Garg, S. K., Heinemann, L., Hirsch, I. B., Kovatchev, B. P., Laffel, L. M., Mohan, V., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0375 · Cited by 135
Self-citationMcCall, A. L., Lieb, D. C., Gianchandani, R. Y., MacMaster, H. W., Maynard, G. A., Murad, M. H., Seaquist, E. R., Wolfsdorf, J. I., Wright, R. F., & Wiercioch, W. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac596 · Cited by 145
Aleppo, G., Laffel, L. M., Ahmann, A., Hirsch, I. B., Kruger, D. F., Peters, A. L., Weinstock, R. S., & Harris, D. R. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00388 · Cited by 136
Self-citation2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 149
Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners
Ajjan, R., Slattery, D., & Wright, E. E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0870-x · Cited by 140
Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P. (2024) · Diabetes Care · doi:10.2337/dc23-1520 · Cited by 124
Aronson, R., Brown, R. E., Chu, L., Bajaj, H. S., Khandwala, H., Abitbol, A., Malakieh, N., & Goldenberg, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14949 · Cited by 118
Self-citationContinuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
Janapala, R. N., Jayaraj, J. S., Fathima, N., Kashif, T., Usman, N., Dasari, A., Jahan, N., & Sachmechi, I. (2019) · Cureus · doi:10.7759/cureus.5634 · Cited by 117
Peralta, F. G., Choudhary, P., Cosson, E., Irace, C., Rami-Merhar, B. M., & Seibold, A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14638 · Cited by 121
Bergenstal, R. M., Layne, J. E., Zisser, H., Gabbay, R. A., Barleen, N. A., Lee, A. A., Majithia, A. R., Parkin, C. G., & Dixon, R. F. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0396 · Cited by 114
Self-citationJohnson, M. L., Martens, T. W., Criego, A. B., Carlson, A. L., Simonson, G. D., & Bergenstal, R. M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0034 · Cited by 116
Self-citationType 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
“Effect of rtCGM on lifestyle modification Lifestyle modification is recommended as the first step in the management of prediabetes and T2D.27 There is evidence in the literature demonstrating that rtCGM use contributes to patient education and assists with behavioral change, indi- cating it may be an effective teachin…”
BackgroundSelf-citationEhrhardt, N. M., & Zaghal, E. A. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818790994 · Cited by 117
Artificial intelligence for diabetes care: current and future prospects
Sheng, B., Pushpanathan, K., Guan, Z., Lim, Q. H., Lim, Z. W., Yew, S. M. E., Goh, J. H. L., Bee, Y. M., Sabanayagam, C., Sevdalis, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00154-2 · Cited by 106
Taylor, P. J., Thompson, C. H., & Brinkworth, G. D. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12807 · Cited by 115
Park, C., & Le, Q. A. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0177 · Cited by 109
Zahedani, A. D., McLaughlin, T., Veluvali, A., Aghaeepour, N., Hosseinian, A., Agarwal, S., Ruan, J., Tripathi, S., Woodward, M., Hashemi, N., et al. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00956-y · Cited by 96
Benefits and Challenges of Diabetes Technology Use in Older Adults
Toschi, E., & Munshi, M. N. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.001 · Cited by 102
Self-citationTime in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Yoo, J. H., & Kim, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0257 · Cited by 107
CGMap: Characterizing continuous glucose monitor data in thousands of non-diabetic individuals
Keshet, A., Shilo, S., Godneva, A., Talmor‐Barkan, Y., Aviv, Y., Segal, E., & Rossman, H. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.04.002 · Cited by 105
Technology in the management of type 2 diabetes: Present status and future prospects
DALY, A. B., & Hovorka, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14418 · Cited by 107
Kröger, J., Fasching, P., & Hanaire, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00741-9 · Cited by 90
Ferreira, R. O. M., Trevisan, T., Pasqualotto, E., Chavez, M. P., Marques, B. F., Lamounier, R. N., & van de Sande-Lee, S. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0390 · Cited by 92
Ida, S., Kaneko, R., & Murata, K. (2019) · Journal of Diabetes Research · doi:10.1155/2019/4684815 · Cited by 95
Yoo, J. H., & Kim, J. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0271 · Cited by 117
Paris, I., Henry, C., Pirard, F., Gérard, A., & Colin, I. M. (2018) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.23 · Cited by 84
Evolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
Kudva, Y. C., Raghinaru, D., Lum, J. W., Graham, T. E., Liljenquist, D., Spanakis, E. K., Pasquel, F. J., Ahmann, A., Ahn, D. T., Aleppo, G., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415948 · Cited by 83
Self-citationAleppo, G., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1304 · Cited by 82
Self-citationAjjan, R. A., Jackson, N., & Thomson, S. A. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119827456 · Cited by 79
“Sensor insertion-site signs and symptoms (n = 42) experienced by 29 participants (36 mild and 6 moderate) were primarily associated with sensor wear; erythema (16), itching (10) and rash (4).”
BackgroundLin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Bao, S., Bailey, R., Calhoun, P., & Beck, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0494 · Cited by 81
Self-citationA virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits
Dixon, R. F., Zisser, H., Layne, J. E., Barleen, N. A., Miller, D. P., Moloney, D. P., Majithia, A. R., Gabbay, R. A., & Riff, J. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819888662 · Cited by 80
Mayberry, L. S., Guy, C., Hendrickson, C. D., McCoy, A. B., & Elasy, T. A. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08222-3 · Cited by 91
Price, D. A., Deng, Q., Kipnes, M., & Beck, S. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01086-y · Cited by 77
Self-citationCurrent Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified
Anderson, J. E., Gavin, J. R., & Kruger, D. F. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0303 · Cited by 84
Self-citationUhl, S., Choure, A., Rouse, B., Loblack, A., & Reaven, P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad652 · Cited by 76
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Welsh, J. B., Gao, P., Derdzinski, M., Puhr, S., Johnson, T. K., Walker, T. C., & Graham, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0374 · Cited by 72
Oser, T. K., Hall, T. L., Dickinson, L. M., Callen, E. F., Carroll, J. K., Nease, D. E., Michaels, L. C., & Oser, S. M. (2022) · The Annals of Family Medicine · doi:10.1370/afm.2876 · Cited by 90
Lind, N., Christensen, M. B., Hansen, D. L., & Nørgaard, K. (2024) · Diabetes Care · doi:10.2337/dc23-2194 · Cited by 81
Digital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position
Smokovski, I., Steinle, N., Behnke, A., Bhaskar, S. M. M., Grech, G., Richter, K., Niklewski, G., Birkenbihl, C., Parini, P., Andrews, R. J., et al. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00364-6 · Cited by 80
Joseph, J. I. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820911919 · Cited by 81
Carlson, A. L., Daniel, T. D., DeSantis, A., Jabbour, S. A., French, E. K., Kruger, D. F., Miller, E. M., Özer, K., & Elliott, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002590 · Cited by 77
Self-citationMoon, S. J., Kim, K., Lee, W. J., Lee, M. Y., Vigersky, R., & Park, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14852 · Cited by 69
Continuous Glucose Monitoring As a Behavior Modification Tool
Ehrhardt, N. M., & Zaghal, E. A. (2020) · Clinical Diabetes · doi:10.2337/cd19-0037 · Cited by 80
Reaven, P. D., Newell, M., Rivas, S., Zhou, X., Norman, G. J., & Zhou, J. (2023) · Diabetes Care · doi:10.2337/dc22-2189 · Cited by 79
Reddy, N., Verma, N., & Dungan, K. M. (2020) · MDText.com, Inc. eBooks · Cited by 108
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Yu, J. S., Lee, S.-H., & Kim, M. K. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.105 · Cited by 85
Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features
Aktürk, H. K., Dowd, R., Shankar, K., & Derdzinski, M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0654 · Cited by 69
Zhu, T., Kuang, L., Piao, C., Zeng, J., Li, K., & Georgiou, P. (2024) · IEEE Transactions on Biomedical Circuits and Systems · doi:10.1109/tbcas.2023.3348844 · Cited by 75
Metadata
- Authors
- Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., Aronson, R., Toschi, E., Kollman, C., Bergenstal, R., & for the DIAMOND Study Group*
- Affiliations
- Joslin Diabetes Center (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-09-19
- Volume
- 167
- Issue
- 6
- Pages
- 365-374
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2753830550
- Semantic Scholar
- 4f35ac21c54271e1101cc587d928e543765ee06a
- Cited by
- 635
- References
- 31
- Citations by year
- 2026: 58 · 2025: 91 · 2024: 95 · 2023: 77 · 2022: 77 · 2021: 85 · 2020: 43 · 2019: 56 · 2018: 46 · 2017: 6
- FWCI
- 32.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, type 2 diabetes, multiple daily insulin injections, glycemic control, HbA1c reduction, hypoglycemia, quality of life, usual care, type 1 diabetes
- MeSH terms
- Adult, Aged, Bacterial Proteins, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Membrane Proteins, Middle Aged, Quality of Life, Blood Glucose Self-Monitoring, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.